Physician profile
Peter Logalbo
NPI 1700825395
$3,644.03
in general payments reported to CMS, 2019-2025
26 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $476 · 2021: $173 · 2022: $543 · 2023: $1,091 · 2024: $564 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778 · Education: $94.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.15 |
| Education | $94.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $748.22 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $375.14 | 2019-2023 | Dupixent |
| Glaxosmithkline, LLC. | $355.05 | 2019-2024 | Nucala, Trelegy Ellipta |
| Kaleo, INC. | $307.57 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $278.72 | 2019-2024 | |
| Genzyme Corporation | $229.46 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $218.15 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.90 | 2022-2024 | Cuvitru, Hyqvia |
| Grifols USA, LLC | $141.15 | 2020-2024 | Xembify |
| Genentech USA, INC. | $131.67 | 2019-2023 | Xolair |
| Amgen INC. | $104.84 | 2022-2024 | Tezspire |
| Pfizer INC. | $97.22 | 2019-2023 | |
| Ars Pharmaceuticals Operations, INC. | $85.79 | 2025 | Neffy |
| Inspire Medical Systems, INC. | $72.00 | 2023-2024 | Inspire |
| Stryker Corporation | $57.77 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $54.60 | 2019-2020 | |
| Aerin Medical INC. | $35.20 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $34.57 | 2020 | |
| Csl Behring | $29.85 | 2025 | Haegarda |
| Blueprint Medicines Corporation | $24.16 | 2023 | Ayvakit |
| Aimmune Therapeutics, INC. | $22.34 | 2020 | |
| Phadia US INC. | $20.09 | 2024 | Immunocap |
| Acclarent, INC | $18.57 | 2020 | |
| Pharming Healthcare, INC. | $17.90 | 2024 | Ruconest |
| Hikma Pharmaceuticals USA | $15.10 | 2023 | Ryaltris |
| Glenmark Therapeutics INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Logalbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.